Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among which is the meta-analysis of data from the PROTECTED TAVR and BHF PROTECT TAVI Trials
Background
The embolisation of debris after transaortic valve implantation (TAVI) for the treatment of aortic stenosis can lead to stroke. Cerebral embolic protection (CEP) devices, which can capture this debris and thus lower the incidence of stroke, have been deployed during TAVI, however, results from their use have been seen as inconclusive.
Recent trials, such as the PROTECTED TAVR 1 and BHF PROTECT-TAVI 2 have demonstrated no significant difference between the control arm and the CEP arm within 72 hours after TAVI or TAVR.
The current meta-analysis presented by Prof. Rajesh Kharbanda combines the results of both trials to better understand these results and allow for more definitive research for the future use of CEP in these interventions.
Results
Key learnings
Choice of device
SENTINEL™ device (Boston Scientific)
Conclusions and PCR recommendations
Despite a clear rationale leading to the development of CEP, this meta-analysis of individual data from 2 large RCTs (PROTECTED TAVR and BHF-PROTECT-TAVI) clearly demonstrated that there was no benefit of the routine use of CEP with the SENTINEL device during TAVI to reduce the risk of peri-procedural stroke.
The meta-analysis leads to several key points for future studies:
References
NOTES TO EDITORS
Key information
People